Early detection of colorectal and gastric cancers could dramatically improve survival rates for the 1.6 million people diagnosed annually with these deadly diseases. Current screening methods are invasive, expensive, or require separate testing for each cancer type, creating barriers to widespread adoption. A breakthrough blood-based screening approach addresses these limitations by simultaneously detecting both cancers from a single sample. The tMCTA-seq technique analyzes DNA methylation patterns in 110 specific genetic locations within circulating cell-free DNA fragments that tumors shed into the bloodstream. Testing on 448 plasma samples revealed the method achieved 88.2% sensitivity for colorectal cancer detection with 90.7% specificity, while gastric cancer detection reached 86.7% sensitivity with 94.4% specificity. The approach can even distinguish between the two cancer types with 82% accuracy. This methylation-based detection represents a significant advancement in liquid biopsy technology. Unlike traditional screening colonoscopies or endoscopies, this method requires only a blood draw and could enable population-level screening at significantly lower cost. The technique's ability to detect cancer DNA at concentrations below one genome equivalent demonstrates exceptional analytical sensitivity. However, the study's relatively small sample size and single-institution design limit immediate clinical translation. Larger multicenter trials across diverse populations will be essential to validate performance and establish this as a viable alternative to current screening protocols. If confirmed, this dual-cancer detection capability could transform gastrointestinal cancer screening from reactive, symptom-driven testing to proactive, accessible early detection.